Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

1
Aarkstore.com Alzheimers Disease Biomarkers in
Cerebrospinal Fluid and Blood, 2011
2
Summary

• This report provides an overview of biomarkers
  associated with Alzheimers disease (AD) found in
  cerebrospinal fluid and blood, that have
  potential in differential diagnosis, in following
  treatment, in clinical trials and drug discovery.
  AD biomarkers offer utility in a number of
  ways identification of groups at risk of
  developing AD early detection of AD
  differentiation of different forms of
  neurodegenerative disease from AD, as well as
  developmental stages (such as MCI), thought to
  progress to AD supporting specific treatments or
  pharmacological interventions following the
  time-course progression of AD and response to
  therapy assessing patient prognosis advancing
  understanding of the disease, including risk
  factors, and the changes that precede its
  development the identification of new drug
  targets and candidate molecules development of
  discovery assays for efficacy or toxicity
  markers and supporting the recruitment of
  subjects most likely to provide a meaningful
  analysis of treatment effects. These areas are,
  therefore, considered and discussed in relation
  to the AD biomarkers presented in this report.
  Of the biomarker areas being researched, the
  goal of developing methods for the early
  detection of AD, including the prediction of risk
  in particular patient groups, is a key priority.
  It is believed that the first symptoms of AD
  generally diagnosed using cognitive, behavioural
  and functional assessments occur after
  significant neuronal loss has already occurred.

3
Table of Contents

• Index Page Chapter 1 Background 18 1.
  Alzheimers Disease 19 1.1 Statistics and Costs
  19 1.2 Histopathology 20 1.3 Amyloid Beta
  (Abeta) 20 1.4 Tau Proteins and Neurofibrillary
  Tangles 21 1.5 Cholinergic Hypothesis 22 1.6
  Diagnosis 22 1.7 Cognitive Tests 23 1.8 Stages
  of Alzheimers Disease 25 1.9 Treatment of AD 25
  1.10 Biomarkers 26 1.11 Genetics 27 Chapter 2
  CSF Biomarkers and Diagnosis 33-47 Chapter 3
  Blood Biomarkers and Diagnosis 52-62 Chapter 4
  CSF Biomarkers and Early Detection 65-75 Chapter
  5 Blood Biomarkers and Early Detection 74-80
  Chapter 6 Discussion 83-89

4
More Related Reports

•   VEGF Inhibition Therapy-Indicating and
  Prognostic Biomarkers, 2011
•   Biomarkers in Alzheimers Disease, 2011
•   Alzheimers Disease Autoantibodies, Vaccines
  and Therapeutic Antibodies Pipeline, 2011
•   Prostate Cancer Vaccines and Therapeutic
  Antibodies Pipeline, 2011
•   Breast Cancer Vaccines and Therapeutic
  Antibodies Pipeline, 2011
•   Alzheimers Disease Biomarkers in Cerebrospinal
  Fluid and Blood, 2011
•   Image-Based Biomarkers in Alzheimers Disease,
  2011
•   Lung Cancer Vaccines and Therapeutic
  Antibodies Pipeline, Strategies and Clinical

5
For More details

• http//www.aarkstore.com/reports/Alzheimers-Diseas
  e-Biomarkers-in-Cerebrospinal-Fluid-and-Blood-2011
  -146443.html
• Vina
• Aarkstore.com
• Contact Marketing team
• Mob.No.918149852585
• Email enquiry_at_aarkstore.com
• URL http//www.aarkstore.com/
• XML http//www.aarkstore.com/feeds/Biopharmrepor
  ts.xml